[Amplification of N-myc in neuroblastoma: paradigm for clinical use of an oncogene alteration].
Increase of the dosage of cellular oncogens by DNA amplifications is a frequent genetic alteration of cancer cells. The presence of amplified cellular oncogenes is usually signalled by conspicuous chromosomal abnormalities, "double minutes" (DMs) or "homogeneously staining regions (HSRs). Some human cancers carry a specific amplified oncogene at high incidence. Particularly in neuroblastomas and in breast cancers the amplification of cellular oncogenes has been found associated with aggressively growing cancers and is an indicator for poor prognosis. Neuroblastoma, a malignant tumor of the sympathetic nervous system of children, frequently carries amplification of the oncogene MYCN. The amplification of MYCN is of predictive value for identifying high risk neuroblastoma patients that require specific therapeutic regimen and is generally viewed as the first oncogene alteration that turned out to be of practical clinical significance.
Schwab
M
M
Institut für Experimentelle Pathologie, Deutsches Krebsforschungszentrum.
D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D002648:Child; D002869:Chromosome Aberrations / Q000235:genetics*; D005784:Gene Amplification / Q000235:genetics*; D006801:Humans; D009447:Neuroblastoma / Q000235:genetics*; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016271:Proto-Oncogene Proteins c-myc
D011518:Proto-Oncogene Proteins; D016271:Proto-Oncogene Proteins c-myc
Amplifikation von MYCN in Neuroblastomen: Paradigma für die klinische Anwendung einer Onkogenveränderung.